Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Allergan plc Ordinary Shares (NYSE:AGN)’s Botox Gets FDA Approval For Third Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 04:15pm CEST

Allergan plc Ordinary Shares (NYSE:AGN)’s Botox has received the approval of the U.S. Food and Drug Administration for a third indication – improving the facial appearance of adults who have particular forehead lines. Other indications for which the FDA has given approval for Botox include the treatment of glabellar lines and crow’s feet. This now makes Botox the sole neurotoxin approved for use in treating three distinct facial areas.

The decision to approve Botox for a third indication came after two clinical trials where the effectiveness of the treatment was compared to a placebo within a period of 30 days. In the first trial the primary endpoint was met by 61% of participants.

Aesthetics market

According to the chief executive officer of Allergan, Brent Saunders, the FDA approval will give the pharmaceutical company yet another opportunity in the aesthetics market which in his own words is the world’s best market.

“It’s high-quality, it’s cash-pay, it’s global. We are just at the initial stages of market development in the U.S. and almost every market in the world. So we have very high conviction around the sustainability,” Saunders is quoted as saying in an earnings call earlier in the year.

In this year’s first half, Botox generated approximately $1.53 billion in sales. This was an improvement of 12.7% compared to a year ago and was largely driven by strong demand. Now approved for the treatment of forehead lines, sales should rise even higher.

Body contouring

To bolster Allergan’s lineup in the aesthetics market, the pharmaceutical giant earlier in the year indicated that it was acquiring Zeltiq, a body contouring firm, at a price of $2.47 billion. Earlier in the year Allergan got Rhofade, a new rosacea treatment, approved. Three months ago the treatment had notched a familiarity rate of 75% among practices.

Additionally Allergan is involved in the development of Botox as a solution or particular medical cases such as prevention of chronic migraines. In Allergan’s line-up of aesthetics treatments the one product that has not been performing well is Kybella, a chin fat-buster.

On Wednesday shares of Allergan Plc fell by 0.67% to close the day at $208.39.

The post Allergan plc Ordinary Shares (NYSE:AGN)’s Botox Gets FDA Approval For Third Indication appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
01:31pALLERGAN : Announces FDA Acceptance of Supplemental New Drug Application For VRA..
09/20ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
09/20ALLERGAN : Unveils Spotlyte™, A First-In-Category Digital Hub Designed To ..
09/20ALLERGAN : to Host Medical Aesthetics Day Event on September 14, 2018
09/20ALLERGAN : Study Results from Allergan Update Understanding of Acute Kidney Inju..
09/20ALLERGAN : Teams Up with Actor Scott Eastwood to Encourage Recognition of World ..
09/20ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic (onabotulinumtoxinA) ..
09/19ALLERGAN : Announces Plans to Build First Medical Aesthetics Innovation Center i..
09/19ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic for the Treatment of ..
09/19ALLERGAN : Highlights Key Growth Drivers for Medical Aesthetics
More news
News from SeekingAlpha
08:12aAllergan announces FDA acceptance of supplemental new drug application for VR.. 
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
09/18Allergan Snaps Up Early Stage Startup, Goes Back To Its Aesthetic Roots 
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
Financials ($)
Sales 2018 15 523 M
EBIT 2018 7 411 M
Net income 2018 -1 186 M
Debt 2018 23 063 M
Yield 2018 1,47%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,59x
EV / Sales 2019 5,35x
Capitalization 63 680 M
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 212 $
Spread / Average Target 13%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC16.95%63 680
JOHNSON & JOHNSON2.26%371 937
PFIZER20.90%256 702
NOVARTIS-0.63%219 947
ROCHE HOLDING LTD.-4.20%211 344
MERCK AND COMPANY25.79%187 895